Zhejiang Starry Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 603520.SS

Zhejiang Starry Pharmaceutical Co.,Ltd. Current Liabilities for the year ending December 31, 2023: USD 412.89 M

Zhejiang Starry Pharmaceutical Co.,Ltd. Current Liabilities is USD 412.89 M for the year ending December 31, 2023, a 3.24% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Zhejiang Starry Pharmaceutical Co.,Ltd. Current Liabilities for the year ending December 31, 2022 was USD 399.92 M, a 34.73% change year over year.
Zhejiang Starry Pharmaceutical Co.,Ltd. Current Liabilities for the year ending December 31, 2021 was USD 296.83 M, a 26.99% change year over year.
Zhejiang Starry Pharmaceutical Co.,Ltd. Current Liabilities for the year ending December 31, 2020 was USD 233.74 M, a 2.17% change year over year.
Zhejiang Starry Pharmaceutical Co.,Ltd. Current Liabilities for the year ending December 31, 2019 was USD 228.78 M, a 24.77% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shanghai Stock Exchange: 603520.SS

Zhejiang Starry Pharmaceutical Co.,Ltd.

CEO	Mr. Weiyi Shen
IPO Date	March 9, 2016
Location	China
Headquarters	Xianju modern industrial cluster
Employees	1,845
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.

Key trends

Past 5 years